What have we learned about the equivalency and outcome-based efficacy of biosimilars within the context of a “single switch” between the originator and biosimilar, including the NOR- SWITCH study; and what are the implications for clinical practice?

What have we learned about the equivalency and outcome-based efficacy of biosimilars within the context of a “single switch” between the originator and biosimilar, including the NOR- SWITCH study; and what are the implications for clinical practice?

What have we learned about the equivalency and outcome-based efficacy of biosimilars within the context of a “single switch” between the originator and biosimilar, including the NOR- SWITCH study; and what are the implications for clinical practice?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Jonathan Kay, MD

Jonathan Kay, MD

Director of Clinical Research
Rheumatology Division
Professor of Medicine
University of Massachusetts Medical School
Worcester, MA